ClinicalTrials.gg
CompletedNCT07167082PRO-HANDUpdated Oct 9, 2026

Multidomain Bedside Assessment of Short-Term Mortality and Readmission in Hospitalized Patients With Metastatic Cancer

An observational study in Cancer, Hospitalizations and Sarcopenia, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Ankara Etlik City Hospital · Observational

How we know

Updated Oct 9, 2026Start date movedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
233
Ages
18 Years and older
Sex
All
01

Study summary

This prospective observational study evaluated whether simple bedside assessments performed during an unplanned hospitalization were associated with short-term outcomes in adults with metastatic solid cancer. The assessments included handgrip strength, blood-based cachexia and inflammatory-metabolic indices, body composition measured by bioelectrical impedance analysis, and patient-reported and nutritional measures.

The primary outcome was death from any cause within 30 days of the index hospital admission. Additional outcomes were death from any cause within 90 days and the first unplanned hospital readmission within 30 days after live discharge. The study aimed to determine whether different bedside domains were associated with mortality and readmission and whether these associations differed across outcomes.

Participants received usual clinical care, and no treatment was assigned by the study.

Read the detailed description

This prospective observational cohort study was conducted in the medical oncology inpatient unit of Ankara Etlik City Hospital. Consecutive adults aged 18 years or older with histologically or cytologically confirmed metastatic solid cancer undergoing unplanned hospitalization were assessed for eligibility.

Study assessments were performed during the index hospitalization. Laboratory values used to calculate composite indices were obtained within the first 24 hours of admission. Handgrip strength testing, bioelectrical impedance analysis, patient-reported measures, and nutritional assessment were performed within the first 48 hours of admission and, whenever clinically feasible, before initiation of new inpatient therapeutic interventions.

Handgrip strength was measured using a calibrated hydraulic hand dynamometer with the patient seated, the elbow flexed at 90 degrees, and the wrist in a neutral position. Three measurements of the dominant hand were obtained at 60-second intervals, and the highest value was retained for analysis.

The two primary composite bedside exposures were the handgrip strength-cachexia index and the standardized C-reactive protein-triglyceride-glucose index. Body-composition measures obtained by bioelectrical impedance analysis included phase angle, fat-free mass, fat mass, skeletal muscle mass, and total body water. Patient-reported and nutritional assessments included the Functional Assessment of Cancer Therapy-General, the Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls questionnaire, the Pittsburgh Sleep Quality Index, resting pain assessed using a visual analog scale, appetite impairment assessed using a visual analog scale, and the Patient-Generated Subjective Global Assessment.

The primary outcome was 30-day all-cause mortality measured from the date of index admission. Additional outcomes were 90-day all-cause mortality and the first unplanned inpatient readmission within 30 days after live discharge. Planned admissions for anticancer treatment, scheduled procedures, day-case therapy, emergency department visits without inpatient admission, and observation stays were not counted as unplanned readmissions.

The study evaluated whether cachexia-related, inflammatory-metabolic, body-composition, patient-reported, and nutritional bedside measures were associated with short-term mortality and unplanned readmission. The study was observational and did not assign or modify anticancer or supportive treatment.

02

Conditions studied

  • Cancer
  • Hospitalizations
  • Sarcopenia
  • Cachexia; Cancer; Sarcopenia

Keywords

  • Hand Grip Strength
  • Prognosis
  • Hospitalized Cancer Patients
  • Cachexia
  • Malnutrition
  • Functional Decline
  • Mortality
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 233 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consisted of adults aged 18 years or older with histologically or cytologically confirmed metastatic solid cancer who underwent unplanned admission to the medical oncology inpatient unit of Ankara Etlik City Hospital. Consecutive eligible patients were enrolled during the recruitment period. Bedside assessments, including handgrip strength, bioelectrical impedance analysis, patient-reported measures, and nutritional assessment, were performed within the first 48 hours of index hospitalization.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • or cytologically confirmed solid cancer
  • Unplanned admission to the medical oncology inpatient unit
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Receiving curative-intent treatment without distant disease
  • Estimated of less than 48 hours at the time of admission, as judged by the treating oncologist
  • Unable or unwilling to provide written
  • Impaired consciousness or inability to cooperate with bedside assessments
  • to bioelectrical impedance analysis according to the study protocol, including implanted cardiac electronic devices or metallic implants that precluded bioelectrical impedance assessment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
233 participants (actual)
Patient registry
No

Groups and cohorts

  • Hospitalized Patients With Metastatic Solid Cancer

    This cohort consisted of adults aged 18 years or older with histologically or cytologically confirmed metastatic solid cancer undergoing unplanned hospitalization in the medical oncology inpatient unit. Bedside assessments, including handgrip strength, bioelectrical impedance analysis, patient-reported measures, and nutritional assessment, were performed within the first 48 hours of the index hospitalization. Participants were followed for 30-day all-cause mortality, 90-day all-cause mortality, and the first unplanned hospital readmission within 30 days after live discharge.

    Other: Handgrip Strength Assessment

Interventions

  • OtherHandgrip Strength Assessment

    Handgrip strength was measured within the first 48 hours of the index hospitalization using a calibrated hydraulic hand dynamometer. Measurements were performed on the dominant hand with the patient seated, the elbow flexed at 90 degrees, and the wrist in a neutral position. Three measurements were obtained at 60-second intervals, and the highest value was retained for analysis. Measurement was deferred when acute injury or recent surgery involved the dominant upper extremity.

06

What researchers measure

Primary outcomes

  1. 30-day All-Cause Mortality

    All-cause mortality within 30 days of the index hospital admission. Mortality was assessed from the date of index admission using hospital records and structured follow-up. All enrolled participants were included in this outcome assessment.

    Time frame: 30 days after index hospital admission

Secondary outcomes

  1. 90-Day All-Cause Mortality

    All-cause mortality within 90 days of the index hospital admission. Mortality was assessed from the date of index admission using hospital records and structured follow-up. All enrolled participants were included in this outcome assessment.

    Time frame: 90 days after index hospital admission

  2. 30-Day Unplanned Hospital Readmission After Live Discharge

    The first unplanned inpatient hospital readmission occurring within 30 days after live discharge from the index hospitalization. Emergency department visits or observation stays without inpatient admission and planned admissions for systemic anticancer treatment, day-case therapy, scheduled procedures, or other elective care were not considered unplanned readmissions. This outcome was evaluated among participants discharged alive from the index hospitalization.

    Time frame: 30 days after live discharge from index hospitalization

07

Study locations

1 site
  • Etlik City Hospital, Medical Oncology Department
    Ankara, Yenimahalle 06210, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Nov 2025, 11 months.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's 11 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Sep 2024 → Dec 2024, primary completion Mar 2025 → Nov 2025 and completion Mar 2025 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2025
First posted
Sep 11, 2025
StartActual
Dec 10, 2024was Sep 2024
Primary completionActual
Nov 14, 2025was Mar 2025
CompletionActual
Jan 13, 2026was Mar 2025
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2024→Dec 10, 2024
Oct 9, 2026
Primary completion
Mar 25, 2025→Nov 14, 2025
Oct 9, 2026
Study completion
Mar 25, 2025→Jan 13, 2026
Oct 9, 2026
Eligibility
Criteria largely rewritten (17 changes)
What changed in the criteria
Inclusion criteria
  • EditedAdults agedAge 18 years andor older
  • RemovedPathologically confirmed diagnosis of cancer
  • RemovedHospitalized with an expected hospital stay of more than 48 hours
  • AddedHistologically or cytologically confirmed metastatic solid cancer
  • AddedUnplanned admission to the medical oncology inpatient unit
  • EditedAbility and willingness to provide written informed consent
Exclusion criteria
  • RemovedDiagnosis of anorexia nervosa
  • RemovedAcute pancreatitis or acute liver failure at admission
  • RemovedHistory of gastric bypass surgery
  • RemovedPresence of chronic active infections
  • RemovedHistory of solid organ transplantation
  • RemovedPregnant or breastfeeding women
  • AddedReceiving curative-intent treatment without distant metastatic disease
  • AddedEstimated life expectancy of less than 48 hours at the time of admission, as judged by the treating oncologist
  • AddedUnable or unwilling to provide written informed consent
  • AddedImpaired consciousness or inability to cooperate with bedside assessments
  • AddedContraindication to bioelectrical impedance analysis according to the study protocol, including implanted cardiac electronic devices or metallic implants that precluded bioelectrical impedance assessment
Oct 9, 2026
Interventions
Added Handgrip Strength Assessment; removed Hand Grip Strength Measurement. Arms added: Hospitalized Patients With Metastatic Solid Cancer; arms removed: Hospitalized Cancer Patients
Oct 9, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frame30-day All-Cause Mortality30 days after hospital admission → 30 days after index hospital admission
  • Description30-day All-Cause Mortality: how it is measured was reworded
Oct 9, 2026
Secondary outcomes
2 added, 6 removed
What changed in the outcomes
  • Added90-Day All-Cause MortalityTime frame: 90 days after index hospital admission
  • Added30-Day Unplanned Hospital Readmission After Live DischargeTime frame: 30 days after live discharge from index hospitalization
  • RemovedIntensive Care Unit AdmissionTime frame: 30 days after hospital admission
  • RemovedHospital ReadmissionTime frame: 30 days after discharge
  • RemovedFunctional Decline - ECOG Performance StatusTime frame: Baseline and 30 days after hospital admission
  • RemovedLength of Hospital StayTime frame: Through initial hospitalization, up to 30 days
  • RemovedMajor ComplicationsTime frame: 30 days after hospital admission
  • RemovedFunctional Decline - Patient-Generated Subjective Global Assessment (PG-SGA)Time frame: Baseline and 30 days after hospital admission
Oct 9, 2026
Title
IntegratedMultidomain Bedside Assessment of Short-Term Mortality and PrognosisReadmission in Hospitalized Patients With Metastatic Cancer
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Sep 1, 2024→Dec 10, 2024
    Primary completion Mar 25, 2025→Nov 14, 2025
    Study completion Mar 25, 2025→Jan 13, 2026
    Eligibility Criteria largely rewritten (17 changes)
    What changed in the criteria
    Inclusion criteria
    • EditedAdults agedAge 18 years andor older
    • RemovedPathologically confirmed diagnosis of cancer
    • RemovedHospitalized with an expected hospital stay of more than 48 hours
    • AddedHistologically or cytologically confirmed metastatic solid cancer
    • AddedUnplanned admission to the medical oncology inpatient unit
    • EditedAbility and willingness to provide written informed consent
    Exclusion criteria
    • RemovedDiagnosis of anorexia nervosa
    • RemovedAcute pancreatitis or acute liver failure at admission
    • RemovedHistory of gastric bypass surgery
    • RemovedPresence of chronic active infections
    • RemovedHistory of solid organ transplantation
    • RemovedPregnant or breastfeeding women
    • AddedReceiving curative-intent treatment without distant metastatic disease
    • AddedEstimated life expectancy of less than 48 hours at the time of admission, as judged by the treating oncologist
    • AddedUnable or unwilling to provide written informed consent
    • AddedImpaired consciousness or inability to cooperate with bedside assessments
    • AddedContraindication to bioelectrical impedance analysis according to the study protocol, including implanted cardiac electronic devices or metallic implants that precluded bioelectrical impedance assessment
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frame30-day All-Cause Mortality30 days after hospital admission → 30 days after index hospital admission
    • Description30-day All-Cause Mortality: how it is measured was reworded
    Secondary outcomes 2 added, 6 removed
    What changed in the outcomes
    • Added90-Day All-Cause MortalityTime frame: 90 days after index hospital admission
    • Added30-Day Unplanned Hospital Readmission After Live DischargeTime frame: 30 days after live discharge from index hospitalization
    • RemovedIntensive Care Unit AdmissionTime frame: 30 days after hospital admission
    • RemovedHospital ReadmissionTime frame: 30 days after discharge
    • RemovedFunctional Decline - ECOG Performance StatusTime frame: Baseline and 30 days after hospital admission
    • RemovedLength of Hospital StayTime frame: Through initial hospitalization, up to 30 days
    • RemovedMajor ComplicationsTime frame: 30 days after hospital admission
    • RemovedFunctional Decline - Patient-Generated Subjective Global Assessment (PG-SGA)Time frame: Baseline and 30 days after hospital admission
    Interventions Added Handgrip Strength Assessment; removed Hand Grip Strength Measurement. Arms added: Hospitalized Patients With Metastatic Solid Cancer; arms removed: Hospitalized Cancer Patients
    Title IntegratedMultidomain Bedside Assessment of Short-Term Mortality and PrognosisReadmission in Hospitalized Patients With Metastatic Cancer
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07167082
Responsible party
Galip Can Uyar (Medical Oncologist, Department of Medical Oncology, Ankara Etlik City Hospital) — Principal investigator
First posted
Sep 11, 2025
Start date
Dec 10, 2024
Primary completion
Nov 14, 2025
Completion
Jan 13, 2026
Last update
Oct 9, 2026

Study contacts

Galip Can Uyar, MD
principal investigator · Ankara Etlik City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion